MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Sunday, April 7, 2013

Biogen Hits Primary Endpoints in MS Study

April 6, 2013
By  


Biotech company Biogen Idec's developmental multiple sclerosis drug daclizumab succeeded in the SELECT phase 2b trial evaluating its safety and effectiveness in treating patients with relapse-remitting MS. The trial results, originally published in The Lancet and reported by Biogen in a recent press statement, showed that two injection treatment groups had annual relapse rates at least 50% lower than a placebo group after one year.
The two treatment groups also showed that daclizumab reduced MS-related brain lesions and improved quality of life in patients, as well as reducing disability progression.
Dr. Gilmore O'Neill, Biogen's vice president of medical research, said of the results, "Based on these initial data from SELECT, we believe DAC HYP would complement our robust portfolio of four approved MS products by potentially offering people with MS a new treatment alternative."
Daclizumab is Biogen's latest developmental candidate in the multiple sclerosis market it has dominated. The company's oral MS treatment, Tecfidera, won FDA approval in late March and is poised to compete in the promising oral MS market.
source: Motley

..


USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register


.

No comments: